Martin Dunn, member of the board of directors of Diaverum and partner at Bridgepoint, commented: “Despite strong interest from potential investors, including several high quality pension funds, who recognised Diaverum’s impressive underlying performance and ability to grow both revenues and earnings year on year, indications received did not fully reflect the fundamental value of the business. For this reason, we have decided to withdraw the IPO.”

Diaverum CEO Dimitris Moulavasilis commented: “Diaverum is a resilient business with a healthy exposure to high-growth markets and great execution capabilities to continue delivering future growth with attractive margins. We welcome the continued support from Bridgepoint as a long-term investor.”